ONTOLOGY REPORT - ANNOTATIONS
| Term: | furosemide |
|
| Accession: | CHEBI:47426
|
browse the term
|
| Definition: | A chlorobenzoic acid that has formula C12H11ClN2O5S. |
| Synonyms: | exact_synonym: | 4-chloro-2-{[(furan-2-yl)methyl]amino}-5-sulfamoylbenzoic acid |
| | related_synonym: | 2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid; 4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid; 4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid; 4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid; C12H11ClN2O5S; Frusemide; InChI=1S/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19); InChIKey=ZZUFCTLCJUWOSV-UHFFFAOYSA-N; Lasix (TN); NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl |
| | alt_id: | CHEBI:47425; CHEBI:5198 |
| | xref_casrn: | 54-31-9 |
| | xref: | ChEMBL:102046 "ChEMBL COMPOUND"; ChemIDplus:54-31-9 "CAS Registry Number"; DrugBank:DB00695 "DrugBank"; KEGG DRUG:54-31-9 "CAS Registry Number"; KEGG DRUG:D00331 "KEGG DRUG" |
| | xref_mesh: | MESH:D005665 |
| | xref: | Wikipedia:Furosemide "Wikipedia" |
|
|
furosemide
|
| G |
Abcc2 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 2 |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Abcc2 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 2 |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Abcc3 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 3 |
|
multiple interactions |
ISO |
10 |
82,986,552 |
83,030,799 |
RGD:6480464 |
CTD |
| G |
Abcc4 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 4 |
|
increases export |
ISO |
15 |
103,384,848 |
103,611,238 |
RGD:6480464 |
CTD |
| G |
Abcc4 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 4 |
|
increases transport |
ISO |
15 |
103,384,848 |
103,611,238 |
RGD:6480464 |
CTD |
| G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
|
affects expression |
EXP |
11 |
25,434,262 |
25,443,144 |
RGD:6480464 |
CTD |
| G |
Agt |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
increases expression |
ISO |
19 |
54,738,556 |
54,750,349 |
RGD:6480464 |
CTD |
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
affects phosphorylation |
EXP |
6 |
137,640,482 |
137,657,552 |
RGD:6480464 |
CTD |
| G |
Alb |
albumin |
|
multiple interactions |
ISO |
14 |
19,126,935 |
19,142,214 |
RGD:6480464 |
CTD |
| G |
Alb |
albumin |
|
affects binding |
ISO |
14 |
19,126,935 |
19,142,214 |
RGD:6480464 |
CTD |
| G |
Ang |
angiogenin, ribonuclease, RNase A family, 5 |
|
affects expression |
EXP |
15 |
27,083,089 |
27,083,526 |
RGD:6480464 |
CTD |
| G |
Angpt2 |
angiopoietin 2 |
|
affects expression |
EXP |
16 |
75,891,757 |
75,942,255 |
RGD:6480464 |
CTD |
| G |
Apaf1 |
apoptotic peptidase activating factor 1 |
|
affects expression |
EXP |
7 |
27,932,908 |
28,020,533 |
RGD:6480464 |
CTD |
| G |
Aqp2 |
aquaporin 2 (collecting duct) |
|
increases expression |
EXP |
7 |
138,325,855 |
138,330,891 |
RGD:6480464 |
CTD |
| G |
Arc |
activity-regulated cytoskeleton-associated protein |
|
affects expression |
EXP |
7 |
112,771,937 |
112,775,381 |
RGD:6480464 |
CTD |
| G |
Atm |
ataxia telangiectasia mutated |
|
affects expression |
EXP |
8 |
56,894,746 |
56,996,565 |
RGD:6480464 |
CTD |
| G |
Atp6v1b1 |
ATPase, H transporting, lysosomal V1 subunit B1 |
|
multiple interactions |
EXP |
4 |
117,931,972 |
117,950,626 |
RGD:6480464 |
CTD |
| G |
Atp6v1b1 |
ATPase, H transporting, lysosomal V1 subunit B1 |
|
increases expression |
EXP |
4 |
117,931,972 |
117,950,626 |
RGD:6480464 |
CTD |
| G |
Avpr2 |
arginine vasopressin receptor 2 |
|
increases expression |
EXP |
X |
159,821,860 |
159,823,488 |
RGD:6480464 |
CTD |
| G |
Bad |
BCL2-associated agonist of cell death |
|
affects expression |
EXP |
1 |
209,617,373 |
209,626,292 |
RGD:6480464 |
CTD |
| G |
Bak1 |
BCL2-antagonist/killer 1 |
|
affects expression |
EXP |
20 |
5,255,954 |
5,264,593 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
affects expression |
EXP |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bcl10 |
B-cell CLL/lymphoma 10 |
|
affects expression |
EXP |
2 |
244,116,880 |
244,126,393 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
affects expression |
EXP |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2l10 |
BCL2-like 10 (apoptosis facilitator) |
|
affects expression |
EXP |
8 |
80,172,804 |
80,178,851 |
RGD:6480464 |
CTD |
| G |
Bcl2l11 |
BCL2-like 11 (apoptosis facilitator) |
|
affects expression |
EXP |
3 |
115,692,323 |
115,722,701 |
RGD:6480464 |
CTD |
| G |
Bcl2l2 |
Bcl2-like 2 |
|
affects expression |
EXP |
15 |
32,983,165 |
32,988,018 |
RGD:6480464 |
CTD |
| G |
Bid |
BH3 interacting domain death agonist |
|
affects expression |
EXP |
4 |
157,296,383 |
157,318,481 |
RGD:6480464 |
CTD |
| G |
Bik |
BCL2-interacting killer (apoptosis-inducing) |
|
affects expression |
EXP |
7 |
121,377,004 |
121,396,609 |
RGD:6480464 |
CTD |
| G |
Birc2 |
baculoviral IAP repeat-containing 2 |
|
affects expression |
EXP |
8 |
4,649,559 |
4,667,733 |
RGD:6480464 |
CTD |
| G |
Birc5 |
baculoviral IAP repeat-containing 5 |
|
affects expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Birc6 |
baculoviral IAP repeat-containing 6 |
|
affects expression |
EXP |
6 |
20,655,186 |
20,848,961 |
RGD:6480464 |
CTD |
| G |
Bok |
BCL2-related ovarian killer |
|
affects expression |
EXP |
9 |
92,970,069 |
92,980,974 |
RGD:6480464 |
CTD |
| G |
Bsnd |
Bartter syndrome, infantile, with sensorineural deafness (Barttin) |
|
decreases expression |
EXP |
5 |
127,542,219 |
127,551,017 |
RGD:6480464 |
CTD |
| G |
Calb1 |
calbindin 1 |
|
increases expression |
ISO |
5 |
30,455,665 |
30,480,122 |
RGD:6480464 |
CTD |
| G |
Casp1 |
caspase 1 |
|
affects expression |
EXP |
8 |
2,027,976 |
2,036,872 |
RGD:6480464 |
CTD |
| G |
Casp12 |
caspase 12 |
|
affects expression |
EXP |
8 |
2,082,933 |
2,110,511 |
RGD:6480464 |
CTD |
| G |
Casp14 |
caspase 14 |
|
affects expression |
EXP |
7 |
12,487,166 |
12,489,998 |
RGD:6480464 |
CTD |
| G |
Casp2 |
caspase 2 |
|
affects expression |
EXP |
4 |
70,029,728 |
70,047,164 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
affects expression |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp4 |
caspase 4, apoptosis-related cysteine peptidase |
|
affects expression |
EXP |
8 |
2,038,626 |
2,075,722 |
RGD:6480464 |
CTD |
| G |
Casp6 |
caspase 6 |
|
affects expression |
EXP |
2 |
227,361,538 |
227,373,844 |
RGD:6480464 |
CTD |
| G |
Casp8 |
caspase 8 |
|
affects expression |
EXP |
9 |
57,389,353 |
57,437,803 |
RGD:6480464 |
CTD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
affects expression |
EXP |
5 |
160,704,234 |
160,721,796 |
RGD:6480464 |
CTD |
| G |
Cd40 |
CD40 molecule, TNF receptor superfamily member 5 |
|
affects expression |
EXP |
3 |
156,092,602 |
156,107,427 |
RGD:6480464 |
CTD |
| G |
Cd70 |
Cd70 molecule |
|
affects expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Cdh5 |
cadherin 5 |
|
decreases expression |
EXP |
19 |
779,350 |
816,108 |
RGD:6480464 |
CTD |
| G |
Chek1 |
checkpoint kinase 1 |
|
affects expression |
EXP |
8 |
37,954,322 |
37,974,748 |
RGD:6480464 |
CTD |
| G |
Chek2 |
checkpoint kinase 2 |
|
affects expression |
EXP |
12 |
45,933,900 |
45,965,427 |
RGD:6480464 |
CTD |
| G |
Chga |
chromogranin A (parathyroid secretory protein 1) |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Cidea |
cell death-inducing DFFA-like effector a |
|
affects expression |
EXP |
18 |
63,871,538 |
63,896,975 |
RGD:6480464 |
CTD |
| G |
Cideb |
cell death-inducing DFFA-like effector b |
|
affects expression |
EXP |
15 |
33,916,472 |
33,920,872 |
RGD:6480464 |
CTD |
| G |
Clcnka |
chloride channel, voltage-sensitive Ka |
|
decreases expression |
EXP |
5 |
160,274,377 |
160,290,369 |
RGD:6480464 |
CTD |
| G |
Col18a1 |
collagen, type XVIII, alpha 1 |
|
decreases expression |
EXP |
20 |
11,920,816 |
11,982,468 |
RGD:6480464 |
CTD |
| G |
Cradd |
CASP2 and RIPK1 domain containing adaptor with death domain |
|
affects expression |
EXP |
7 |
32,504,279 |
32,517,581 |
RGD:6480464 |
CTD |
| G |
Csf3 |
colony stimulating factor 3 (granulocyte) |
|
increases expression |
EXP |
10 |
87,473,990 |
87,476,365 |
RGD:6480464 |
CTD |
| G |
Dffa |
DNA fragmentation factor, alpha subunit |
|
affects expression |
EXP |
5 |
166,179,130 |
166,192,029 |
RGD:6480464 |
CTD |
| G |
Efna5 |
ephrin A5 |
|
increases expression |
EXP |
9 |
101,227,615 |
101,532,696 |
RGD:6480464 |
CTD |
| G |
Fadd |
Fas (TNFRSF6)-associated via death domain |
|
affects expression |
EXP |
1 |
205,010,363 |
205,012,768 |
RGD:6480464 |
CTD |
| G |
Faslg |
Fas ligand (TNF superfamily, member 6) |
|
affects expression |
EXP |
13 |
77,472,950 |
77,480,210 |
RGD:6480464 |
CTD |
| G |
Fgf16 |
fibroblast growth factor 16 |
|
affects expression |
EXP |
X |
93,870,484 |
93,880,067 |
RGD:6480464 |
CTD |
| G |
Fgf2 |
fibroblast growth factor 2 |
|
decreases expression |
EXP |
2 |
123,893,314 |
123,947,136 |
RGD:6480464 |
CTD |
| G |
Fgf4 |
fibroblast growth factor 4 |
|
increases expression |
EXP |
1 |
205,292,272 |
205,293,705 |
RGD:6480464 |
CTD |
| G |
Fgfr4 |
fibroblast growth factor receptor 4 |
|
affects expression |
EXP |
17 |
15,512,144 |
15,527,348 |
RGD:6480464 |
CTD |
| G |
Flt1 |
FMS-related tyrosine kinase 1 |
|
increases expression |
EXP |
12 |
7,858,092 |
8,035,966 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
ISO |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
ISO |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Gabra4 |
gamma-aminobutyric acid (GABA) A receptor, alpha 4 |
|
decreases activity |
EXP |
14 |
39,047,461 |
39,122,531 |
RGD:6480464 |
CTD |
| G |
Gad1 |
glutamate decarboxylase 1 |
|
decreases expression |
EXP |
3 |
52,789,370 |
52,830,038 |
RGD:6480464 |
CTD |
| G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
|
affects expression |
EXP |
4 |
96,649,941 |
96,652,243 |
RGD:6480464 |
CTD |
| G |
Hrk |
harakiri, BCL2 interacting protein (contains only BH3 domain) |
|
affects expression |
EXP |
12 |
39,520,265 |
39,543,901 |
RGD:6480464 |
CTD |
| G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
|
decreases activity |
EXP |
13 |
109,063,491 |
109,089,468 |
RGD:6480464 |
CTD |
| G |
Hus1 |
HUS1 checkpoint homolog (S. pombe) |
|
affects expression |
EXP |
14 |
89,527,997 |
89,542,730 |
RGD:6480464 |
CTD |
| G |
Id1 |
inhibitor of DNA binding 1 |
|
decreases expression |
EXP |
3 |
143,086,162 |
143,087,289 |
RGD:6480464 |
CTD |
| G |
Id3 |
inhibitor of DNA binding 3 |
|
decreases expression |
EXP |
5 |
154,934,138 |
154,935,707 |
RGD:6480464 |
CTD |
| G |
Ifna1 |
interferon, alpha 1 |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Igf1 |
insulin-like growth factor 1 |
|
increases expression |
EXP |
7 |
24,531,669 |
24,605,742 |
RGD:6480464 |
CTD |
| G |
Il10 |
interleukin 10 |
|
decreases secretion |
ISO |
13 |
43,953,900 |
43,957,766 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
decreases secretion |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Itga5 |
integrin, alpha 5 (fibronectin receptor, alpha polypeptide) |
|
decreases expression |
EXP |
7 |
142,254,256 |
142,277,464 |
RGD:6480464 |
CTD |
| G |
Kdr |
kinase insert domain receptor |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Lta |
lymphotoxin alpha (TNF superfamily, member 1) |
|
affects expression |
EXP |
20 |
3,657,842 |
3,659,848 |
RGD:6480464 |
CTD |
| G |
Ltb |
lymphotoxin beta (TNF superfamily, member 3) |
|
affects expression |
EXP |
20 |
3,666,524 |
3,668,369 |
RGD:6480464 |
CTD |
| G |
Ltbr |
lymphotoxin beta receptor (TNFR superfamily, member 3) |
|
affects expression |
EXP |
4 |
161,431,864 |
161,438,265 |
RGD:6480464 |
CTD |
| G |
Mdk |
midkine |
|
increases expression |
EXP |
3 |
76,309,988 |
76,311,345 |
RGD:6480464 |
CTD |
| G |
Mdm2 |
p53 E3 ubiquitin protein ligase |
|
affects expression |
EXP |
7 |
56,996,694 |
57,020,926 |
RGD:6480464 |
CTD |
| G |
Msr1 |
macrophage scavenger receptor 1 |
|
increases expression |
EXP |
16 |
56,278,223 |
56,345,472 |
RGD:6480464 |
CTD |
| G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
|
increases localization |
ISO |
3 |
58,366,693 |
58,394,116 |
RGD:6480464 |
CTD |
| G |
Nol3 |
nucleolar protein 3 (apoptosis repressor with CARD domain) |
|
affects expression |
EXP |
19 |
35,094,345 |
35,096,012 |
RGD:6480464 |
CTD |
| G |
Nos3 |
nitric oxide synthase 3, endothelial cell |
|
affects expression |
EXP |
4 |
6,158,847 |
6,179,441 |
RGD:6480464 |
CTD |
| G |
Nppa |
natriuretic peptide A |
|
decreases expression |
ISO |
5 |
165,074,518 |
165,075,827 |
RGD:6480464 |
CTD |
| G |
Pdgfra |
platelet derived growth factor receptor, alpha polypeptide |
|
affects expression |
EXP |
14 |
35,369,422 |
35,418,126 |
RGD:6480464 |
CTD |
| G |
Pdgfrb |
platelet derived growth factor receptor, beta polypeptide |
|
increases expression |
EXP |
18 |
57,014,475 |
57,053,581 |
RGD:6480464 |
CTD |
| G |
Pecam1 |
platelet/endothelial cell adhesion molecule 1 |
|
increases expression |
EXP |
10 |
96,056,220 |
96,057,232 |
RGD:6480464 |
CTD |
| G |
Pf4 |
platelet factor 4 |
|
decreases expression |
EXP |
14 |
18,812,550 |
18,813,259 |
RGD:6480464 |
CTD |
| G |
Pgf |
placental growth factor |
|
decreases expression |
EXP |
6 |
109,215,540 |
109,226,122 |
RGD:6480464 |
CTD |
| G |
Ptger4 |
prostaglandin E receptor 4 (subtype EP4) |
|
multiple interactions |
ISO |
2 |
54,423,280 |
54,433,907 |
RGD:6480464 |
CTD |
| G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
|
affects expression |
EXP |
3 |
15,343,832 |
15,365,412 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
affects expression |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
increases expression |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
increases expression |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
increases expression |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
increases expression |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Pth |
parathyroid hormone |
|
increases expression |
EXP |
1 |
171,240,596 |
171,243,528 |
RGD:6480464 |
CTD |
| G |
Pth |
parathyroid hormone |
|
multiple interactions |
EXP |
1 |
171,240,596 |
171,243,528 |
RGD:6480464 |
CTD |
| G |
Ptn |
pleiotrophin |
|
affects expression |
EXP |
4 |
64,078,755 |
64,160,135 |
RGD:6480464 |
CTD |
| G |
Ren |
renin |
|
multiple interactions |
ISO |
13 |
46,262,936 |
46,275,213 |
RGD:6480464 |
CTD |
| G |
Ren |
renin |
|
increases activity |
ISO |
13 |
46,262,936 |
46,275,213 |
RGD:6480464 |
CTD |
| G |
Ren |
renin |
|
multiple interactions |
ISO |
13 |
46,262,936 |
46,275,213 |
RGD:6480464 |
CTD |
| G |
Ren |
renin |
|
increases expression |
ISO |
13 |
46,262,936 |
46,275,213 |
RGD:6480464 |
CTD |
| G |
Ren |
renin |
|
multiple interactions |
ISO |
13 |
46,262,936 |
46,275,213 |
RGD:6480464 |
CTD |
| G |
Ren |
renin |
|
increases expression |
ISO |
13 |
46,262,936 |
46,275,213 |
RGD:6480464 |
CTD |
| G |
Ren |
renin |
|
multiple interactions |
ISO |
13 |
46,262,936 |
46,275,213 |
RGD:6480464 |
CTD |
| G |
Ren |
renin |
|
multiple interactions |
ISO |
13 |
46,262,936 |
46,275,213 |
RGD:6480464 |
CTD |
| G |
Ren |
renin |
|
increases expression |
EXP |
13 |
46,262,936 |
46,275,213 |
RGD:6480464 |
CTD |
| G |
Ren |
renin |
|
increases activity |
EXP |
13 |
46,262,936 |
46,275,213 |
RGD:6480464 |
CTD |
| G |
Ren |
renin |
|
increases expression |
EXP |
13 |
46,262,936 |
46,275,213 |
RGD:6480464 |
CTD |
| G |
Ren |
renin |
|
increases secretion |
EXP |
13 |
46,262,936 |
46,275,213 |
RGD:6480464 |
CTD |
| G |
Ren |
renin |
|
increases activity |
ISO |
13 |
46,262,936 |
46,275,213 |
RGD:6480464 |
CTD |
| G |
Ren |
renin |
|
increases expression |
EXP |
13 |
46,262,936 |
46,275,213 |
RGD:6480464 |
CTD |
| G |
Ren |
renin |
|
increases activity |
ISO |
13 |
46,262,936 |
46,275,213 |
RGD:6480464 |
CTD |
| G |
Ren |
renin |
|
multiple interactions |
ISO |
13 |
46,262,936 |
46,275,213 |
RGD:6480464 |
CTD |
| G |
Ren |
renin |
|
increases expression |
ISO |
13 |
46,262,936 |
46,275,213 |
RGD:6480464 |
CTD |
| G |
Ren |
renin |
|
increases activity |
EXP |
13 |
46,262,936 |
46,275,213 |
RGD:6480464 |
CTD |
| G |
Ripk1 |
receptor (TNFRSF)-interacting serine-threonine kinase 1 |
|
affects expression |
EXP |
17 |
37,183,591 |
37,216,533 |
RGD:6480464 |
CTD |
| G |
Rpa3 |
replication protein A3 |
|
affects expression |
EXP |
4 |
33,304,334 |
33,307,365 |
RGD:6480464 |
CTD |
| G |
S100g |
S100 calcium binding protein G |
|
affects expression |
ISO |
X |
52,446,817 |
52,449,342 |
RGD:6480464 |
CTD |
| G |
S1pr1 |
sphingosine-1-phosphate receptor 1 |
|
increases expression |
EXP |
2 |
211,851,304 |
211,855,511 |
RGD:6480464 |
CTD |
| G |
Serpinb5 |
serpin peptidase inhibitor, clade B (ovalbumin), member 5 |
|
increases expression |
EXP |
13 |
13,037,587 |
13,057,785 |
RGD:6480464 |
CTD |
| G |
Serpinf1 |
serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 1 |
|
affects expression |
EXP |
10 |
62,713,441 |
62,739,444 |
RGD:6480464 |
CTD |
| G |
Slc12a1 |
solute carrier family 12 (sodium/potassium/chloride transporters), member 1 |
|
decreases activity |
ISO |
3 |
112,455,897 |
112,534,752 |
RGD:6480464 |
CTD |
| G |
Slc12a5 |
solute carrier family 12 (potassium-chloride transporter), member 5 |
|
decreases activity |
EXP |
3 |
156,006,017 |
156,037,915 |
RGD:6480464 |
CTD |
| G |
Slc12a7 |
solute carrier family 12 (potassium/chloride transporters), member 7 |
|
decreases activity |
ISO |
1 |
30,281,826 |
30,334,183 |
RGD:6480464 |
CTD |
| G |
Slc22a24 |
solute carrier family 22, member 24 |
|
multiple interactions |
EXP |
1 |
210,409,224 |
210,465,549 |
RGD:6480464 |
CTD |
| G |
Slc22a6 |
solute carrier family 22 (organic anion transporter), member 6 |
|
increases expression |
EXP |
1 |
211,294,178 |
211,302,398 |
RGD:6480464 |
CTD |
| G |
Slc22a6 |
solute carrier family 22 (organic anion transporter), member 6 |
|
decreases activity |
ISO |
1 |
211,294,178 |
211,302,398 |
RGD:6480464 |
CTD |
| G |
Slc22a6 |
solute carrier family 22 (organic anion transporter), member 6 |
|
increases secretion |
ISO |
1 |
211,294,178 |
211,302,398 |
RGD:6480464 |
CTD |
| G |
Slc22a7 |
solute carrier family 22 (organic anion transporter), member 7 |
|
multiple interactions |
ISO |
9 |
9,934,309 |
9,940,107 |
RGD:6480464 |
CTD |
| G |
Slc22a8 |
solute carrier family 22 (organic anion transporter), member 8 |
|
decreases activity |
ISO |
1 |
211,269,366 |
211,287,596 |
RGD:6480464 |
CTD |
| G |
Slc22a8 |
solute carrier family 22 (organic anion transporter), member 8 |
|
increases secretion |
ISO |
1 |
211,269,366 |
211,287,596 |
RGD:6480464 |
CTD |
| G |
Slc22a8 |
solute carrier family 22 (organic anion transporter), member 8 |
|
multiple interactions |
EXP |
1 |
211,269,366 |
211,287,596 |
RGD:6480464 |
CTD |
| G |
Slc22a8 |
solute carrier family 22 (organic anion transporter), member 8 |
|
multiple interactions |
ISO |
1 |
211,269,366 |
211,287,596 |
RGD:6480464 |
CTD |
| G |
Slc26a4 |
solute carrier family 26, member 4 |
|
multiple interactions |
EXP |
6 |
49,389,212 |
49,427,000 |
RGD:6480464 |
CTD |
| G |
Slc26a4 |
solute carrier family 26, member 4 |
|
affects localization |
EXP |
6 |
49,389,212 |
49,427,000 |
RGD:6480464 |
CTD |
| G |
Sparc |
secreted protein, acidic, cysteine-rich (osteonectin) |
|
increases expression |
EXP |
10 |
40,809,730 |
40,831,481 |
RGD:6480464 |
CTD |
| G |
Tek |
TEK tyrosine kinase, endothelial |
|
increases expression |
EXP |
5 |
115,047,195 |
115,196,172 |
RGD:6480464 |
CTD |
| G |
Tgfa |
transforming growth factor alpha |
|
increases expression |
EXP |
4 |
120,355,649 |
120,437,772 |
RGD:6480464 |
CTD |
| G |
Tgfb1 |
transforming growth factor, beta 1 |
|
affects expression |
EXP |
1 |
80,894,705 |
80,911,020 |
RGD:6480464 |
CTD |
| G |
Tgfb2 |
transforming growth factor, beta 2 |
|
increases expression |
EXP |
13 |
102,718,703 |
102,818,768 |
RGD:6480464 |
CTD |
| G |
Tgfbr2 |
transforming growth factor, beta receptor II |
|
increases expression |
EXP |
8 |
120,593,595 |
120,680,453 |
RGD:6480464 |
CTD |
| G |
Thbs1 |
thrombospondin 1 |
|
affects expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Thbs2 |
thrombospondin 2 |
|
increases expression |
EXP |
1 |
53,584,406 |
53,613,652 |
RGD:6480464 |
CTD |
| G |
Thbs4 |
thrombospondin 4 |
|
affects expression |
EXP |
2 |
23,010,823 |
23,053,527 |
RGD:6480464 |
CTD |
| G |
Tie1 |
tyrosine kinase with immunoglobulin-like and EGF-like domains 1 |
|
increases expression |
EXP |
5 |
138,945,238 |
138,964,631 |
RGD:6480464 |
CTD |
| G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
|
affects expression |
EXP |
10 |
108,310,473 |
108,358,821 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
decreases secretion |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
affects expression |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
affects expression |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnfrsf11a |
tumor necrosis factor receptor superfamily, member 11a, NFKB activator |
|
affects expression |
EXP |
13 |
11,958,002 |
12,014,371 |
RGD:6480464 |
CTD |
| G |
Tnfrsf1a |
tumor necrosis factor receptor superfamily, member 1a |
|
affects expression |
EXP |
4 |
162,172,563 |
162,185,252 |
RGD:6480464 |
CTD |
| G |
Tnfrsf1b |
tumor necrosis factor receptor superfamily, member 1b |
|
affects expression |
EXP |
5 |
163,666,541 |
163,697,484 |
RGD:6480464 |
CTD |
| G |
Tnfrsf25 |
tumor necrosis factor receptor superfamily, member 25 |
|
affects expression |
EXP |
5 |
169,344,695 |
169,348,961 |
RGD:6480464 |
CTD |
| G |
Tnfrsf8 |
tumor necrosis factor receptor superfamily, member 8 |
|
affects expression |
EXP |
5 |
163,716,462 |
163,762,235 |
RGD:6480464 |
CTD |
| G |
Tnfrsf9 |
tumor necrosis factor receptor superfamily, member 9 |
|
affects expression |
EXP |
5 |
168,071,159 |
168,099,501 |
RGD:6480464 |
CTD |
| G |
Tnfsf10 |
tumor necrosis factor (ligand) superfamily, member 10 |
|
affects expression |
EXP |
2 |
113,204,303 |
113,221,550 |
RGD:6480464 |
CTD |
| G |
Tnfsf11 |
tumor necrosis factor (ligand) superfamily, member 11 |
|
affects expression |
EXP |
15 |
59,397,837 |
59,428,014 |
RGD:6480464 |
CTD |
| G |
Tnfsf12 |
tumor necrosis factor ligand superfamily member 12 |
|
affects expression |
EXP |
10 |
56,503,756 |
56,513,053 |
RGD:6480464 |
CTD |
| G |
Tnfsf13 |
tumor necrosis factor (ligand) superfamily, member 13 |
|
affects expression |
EXP |
10 |
56,499,945 |
56,502,928 |
RGD:6480464 |
CTD |
| G |
Tnfsf8 |
tumor necrosis factor (ligand) superfamily, member 8 |
|
affects expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Tnfsf9 |
tumor necrosis factor (ligand) superfamily, member 9 |
|
affects expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Tpmt |
thiopurine S-methyltransferase |
|
decreases activity |
ISO |
17 |
23,697,900 |
23,714,173 |
RGD:6480464 |
CTD |
| G |
Traf6 |
TNF receptor-associated factor 6, E3 ubiquitin protein ligase |
|
affects expression |
EXP |
3 |
86,827,582 |
86,847,408 |
RGD:6480464 |
CTD |
| G |
Trpv5 |
transient receptor potential cation channel, subfamily V, member 5 |
|
increases expression |
ISO |
4 |
69,361,051 |
69,387,346 |
RGD:6480464 |
CTD |
| G |
Trpv6 |
transient receptor potential cation channel, subfamily V, member 6 |
|
increases expression |
ISO |
4 |
69,331,973 |
69,347,633 |
RGD:6480464 |
CTD |
| G |
Ugt1a1 |
UDP glucuronosyltransferase 1 family, polypeptide A1 |
|
increases expression |
ISO |
9 |
87,091,241 |
87,098,362 |
RGD:6480464 |
CTD |
| G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
|
increases glucuronidation |
ISO |
9 |
87,081,132 |
87,098,362 |
RGD:6480464 |
CTD |
| G |
Vcam1 |
vascular cell adhesion molecule 1 |
|
increases expression |
EXP |
2 |
212,277,654 |
212,297,376 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
affects expression |
EXP |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Vegfc |
vascular endothelial growth factor C |
|
increases expression |
EXP |
16 |
40,624,435 |
40,739,692 |
RGD:6480464 |
CTD |
| G |
Xiap |
X-linked inhibitor of apoptosis |
|
affects expression |
EXP |
X |
3,011,520 |
3,047,798 |
RGD:6480464 |
CTD |
Term paths to the root
|